Bookmark and Share
BioAssay: AID 2247

Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).

Assay Implementation: Meng Wu Ph.D., Melissa Miller, Amy Scott M.S., Shunyou Long M.S., Kaiping Xu M.S., Bill Shi Ph.D., David Meyers Ph.D., Jia Xu Ph.D. ..more
_
   
 Tested Compounds
 Tested Compounds
All(304005)
 
 
Active(1189)
 
 
Inactive(302816)
 
 
 Tested Substances
 Tested Substances
All(304070)
 
 
Active(1189)
 
 
Inactive(302881)
 
 
AID: 2247
Data Source: Johns Hopkins Ion Channel Center (JHICC_TRPC4_Inh)
BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2010-01-13
Modify Date: 2010-03-30

Data Table ( Complete ):           Active    All
Target
Sequence: alternatively spliced Trp4 [Mus musculus]
Description ..   
Protein Family: Transient receptor ion channel II

Gene:TRPC4     Related Protein 3D Structures     More BioActivity Data..
BioActive Compounds: 1189
Depositor Specified Assays
Show more
AIDNameTypeProbeComment
2256Summary of efforts to identify compounds that inhibit transient receptor potential cation channel C4 (TRPC4)summary3 Summary assay for TRPC4 inhibitor assays.
2636Confirmatory screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4)screening Confirmatory screen of TRPC4 inhibitors with 2267 compounds tested in duplicates at the concentration of 10 uM, and 735 of them are active.
2637Second confirmatory screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4)screening Confirmatory screen of TRPC4 inhibitors with 2267 compounds tested in duplicates at the concentration of 1 uM, and 334 of them are active.
434942Confirmation dose response assay for compounds that inhibit transient receptor potential cation channel C4 (TRPC4)confirmatory
434948Specificity screen against TRPC6 for compounds that inhibit transient receptor potential cation channel C4 (TRPC4)screening
434978Second counter screen for compounds that inhibit transient receptor potential cation channel C4 (TRPC4)screening
492981SAR Analysis for the identification of selective inhibitors of the transient receptor potential cation channel C4 (TRPC4) in TRPC6 expressing cells: MPD Assayscreening
492987SAR Analysis for the identification of selective inhibitors of the transient receptor potential cation channel C4 (TRPC4) in TRPC6 expressing cells: MPD Assay CRCconfirmatory
492994SAR Analysis for the identification of selective inhibitors of the transient receptor potential cation channel C4 (TRPC4): Primary HTS assay CRCconfirmatory
492995SAR Analysis for the identification of selective inhibitors of the transient receptor potential cation channel C4 (TRPC4): TRPC4 Serotonin Receptor CRC MPD assayconfirmatory
492996SAR Analysis for the identification of selective inhibitors of the transient receptor potential cation channel C4 (TRPC4): ACh assay CRCconfirmatory
504554SAR Analysis for the identification of selective inhibitors of the transient receptor potential cation channel C6 (TRPC6) in cells expressing TRPC4: C4 assay CRCconfirmatory
504866SAR Analysis for the identification of selective inhibitors of the transient receptor potential cation channel C6 (TRPC6) in cells expressing TRPC4: C4 assay CRC 2confirmatory
Description:
Data Source: Johns Hopkins Ion Channel Center (JHICC)
BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed

Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)
Center Affiliation: Johns Hopkins University, School of Medicine
Screening Center PI: Min Li, Ph.D.
Assay Provider: Michael Zhu, Ph.D., Ohio State University
Network: Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1 R21 NS056942-01
Grant Proposal PI: Michael Zhu, Ph.D., Ohio State University
Assay Implementation: Meng Wu Ph.D., Melissa Miller, Amy Scott M.S., Shunyou Long M.S., Kaiping Xu M.S., Bill Shi Ph.D., David Meyers Ph.D., Jia Xu Ph.D.
HTS execution: Melissa Miller, Amy Scott M.S., Shunyou Long M.S., Kaiping Xu M.S., Meng Wu Ph.D.

Name: Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).

Description:

Transient receptor potential (TRP) channels act as key regulators of many sensory systems including those for thermo-, photo-, and osmosensation [1-3]. A diversity of biological disorders has been linked to TRP channel malfunction ranging from neuropathic pain [4], cardiovascular diseases [5], to other diseases involving sensory physiology [6,7].

The TRP family of cation channels can be separated into seven subtypes according to structural similarity. Members of this family are nonselective cation channels that allow entry of extracellular calcium into cells resulting in a depolarization of membrane potential [8]. The mammalian TRPC (canonical) subfamily is proposed to function as store and second-messenger operated cation channels [9]. Disruption of TRPC may cause aberrant modulation of intracellular calcium and changes in membrane potential leading to activation of transcription factors, apoptosis, vascular contractility, platelet activation, and cardiac hypertrophy. Currently there are few pharmacological modulators of the TRPC family and no compounds known to target specific TRPC isoforms [10].

The objective of the current screen is to identify compounds that block activation of TRPC4 by second-messenger signaling [11] within HEK293 cells that stably express this channel and mu-opioid receptor. Compounds selected as TRPC4 inhibitors will later be counter-screened for specificity.

Principle of the assay

To screen for compounds that inhibit the TRPC4 cation channel, a HEK293 cell line which stably expresses both the TRPC4beta and the mu-Opioid receptor is employed. Stimulation of the mu-Opioid receptor by DAMGO induces activation of TRPC4 through the G alpha signaling pathway. Channel activity is monitored by calcium flux with a commercial Fluo4 kit [11]. Compounds that show decreased Fluo4 fluorescence in the presence of the mu-Opioid receptor activator (DAMGO, in ECmax concentration) are considered inhibitor hits. mu-Opioid receptor inhibitors will be excluded through later counter-screening against HEK293 stable cells expressing the mu-Opioid receptor alone.

Keywords:

TRPC4, mu-Opioid receptor, HTS assay, 384, primary, agonist, activator, potentiator, allosteric, FDSS, Calcium, fluorescence, Kinetic, Fluo 4, JHICC, Johns Hopkins, Molecular Libraries Probe Production Centers Network, MLPCN.


References:
1. Venkatachalam, K., and Montell, C. TRP Channels. Annual Review of Biochemistry 76(1), 387-417 (2007) PMID: 17579562
2. Clapham, D., Julius, D., Montell, C. and Schultz, G. International Union of Pharmacology. XLIX. Nomenclature and structure-function relationships of transient receptor potential channels. Pharmacological Reviews 57(4), 427-450 (2005) PMID: 16382100
3. Reaves, B. J., and Wolstenholme, A. J. The TRP channel superfamily: insights into how structure, protein-lipid interactions and localization influence function. Biochemical Society Transactions 035(1), 77-80 (2007) PMID: 17233605
4. Patapoutian, A., Tate, S., and Woolf, C. J. Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Discov 8(1), 55-68 (2009) PMID: 19116627
5. Vassort G, Alvarez J. Transient receptor potential: a large family of new channels of which several are involved in cardiac arrhythmia. Can J Physiol Pharmacol. 2009 Feb;87(2):100-7.PMID: 19234573
6. Nilius, B. TRP channels in disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1772(8), 805-812 (2007) PMID: 17368864
7. Woudenberg-Vrenken, T. E., Bindels, R. J. M., and Hoenderop, J. G. J. The role of transient receptor potential channels in kidney disease. Nat Rev Nephrol 5(8), 441-449 (2009) PMID: 19546862
8. Zhu, X., Jiang, M., Peyton, M., et al. trp, a Novel Mammalian Gene Family Essential for Agonist-Activated Capacitative Ca2+ Entry. Cell 85(5), 661-671 (1996) PMID: 8646775
9. Abramowitz, J., and Birnbaumer, L. Physiology and pathophysiology of canonical transient receptor potential channels. FASEB J. 23(2), 297-328 (2009) PMID: 18940894
10. Okuhara, D. Y., Hsia, A. Y., and Xie, M. Transient receptor potential channels as drug targets. Expert Opinion on Therapeutic Targets 11(3), 391-401 (2007) PMID: 17298296
11. Miret, Juan J., et al., Multiplexed G-Protein-Coupled Receptor Ca2+ Flux Assays for High-Throughput Screening. J Biomol Screen 2005 10: 780-787 (2005) PMID: 16234348.
12. Zhang, J.-H., T.D.Y. Chung, and K.R. Oldenburg, A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen, 1999. 4(2),67-73. (1999) PMID: 10838414.
13. Malo, N., et al., Statistical practice in high-throughput screening data analysis. Nat Biotech, 2006. 24(2), 167-175 (2006). PMID: 16465162.
Protocol
Assay overview:

The objective of this assay is to identify compounds that inhibit the TRPC4 cation channel. A HEK293 cell line which stably expresses both the TRPC4beta and mu-Opioid receptor was employed, and channel activity was monitored by use of Fluo4, a cell-permeable calcium-sensitive dye. Compounds that inhibit TRPC4 result in a decrease in calcium flux in the presence of a mu-Opioid receptor agonist, DAMGO. This reduction in Ca2+ will result in a decreased fluorescence of Fluo4, as compared to control wells.

The HEK293 stable cell line was seeded into 384-well plates. After overnight incubation, the cells were loaded with a calcium-sensitive dye, Fluo4, followed by an assay buffer wash. Cell plates were then loaded onto a Hamamatsu FDSS 6000 kinetic imaging plate reader, where compounds were added and incubated for 110 seconds, before application of a submaximal concentration of DAMGO. Plates were again incubated for 110 seconds before application of DAMGO at a maximal activating concentration. Real-time fluorescence was then measured for 100 seconds. Library compound effect was evaluated by computing the integrated ratio of each well used for calculation and assignment of a B score for that well (B score Inhibitor Ratio, see Result Definitions, 1). Compounds that affected the fluorescence ratio within two seconds after application were flagged as fluorescent and removed from further analysis (Initial ratio, see Result Definitions, 2). Remaining compounds that scored less than the mean minus three times the standard deviation of the B score Inhibitor Ratio of all library members while also having a positive integrated ratio, were considered to be active as inhibitors of the TRPC4 cation channel.

Protocol for the TRPC4 project:

1. Cell culture: Cells are routinely cultured in DMEM/high glucose medium, supplemented with 10% Heat Inactivated Fetal Bovine Serum (HiFBS), 50 IU/ml penicillin, 50 ug/mL streptomycin, 500 ug/mL G418 and 40 ug/mL hygromycin
2. Cell plating: Add 50 ul/well of 300,000 cells/ml re-suspended in DMEM/high glucose medium with 10% HiFBS.
3. Incubate overnight at 37C and 5% CO2
4. Remove medium and add 20 ul/well of 1x Fluo4 solution to cells
5. Incubate 45 minutes at room temperature (RT) in the dark
6. Prepare 7.5X compound plates and control plates on Cybi-Well system: test compounds are prepared using assay buffer; controls are assay buffer (EC0), and ECmax of DAMGO
7. Remove Fluo4 dye solution and add 40 ul/well of assay buffer to cells
8. Remove 40 ul solution and add 20 ul/well of assay buffer to cells
9. Load cell plates to Hamamatsu FDSS 6000 kinetic imaging plate reader
10. Measure fluorescence for 5 seconds at 1Hz to establish baseline
11. Add 4 ul of 7.5x compound stock into the cell plates.
12. Incubate plates for 110 seconds
13. Add submaximal concentration of DAMGO and incubate for 110 seconds
14. Add maximally activating concentration of DAMGO (DAMGO ECmax) and read for another 110 seconds.
15. Calculate ratio readout as F(max-min)/F0 and integrated ratio readout
16. Calculate the average and standard deviation for negative and positive controls in each plate, as well as Z and Z' factors [12]
17. Calculate B scores [13] for test compounds using integrated ratios calculated in Step 15
18. Outcome assignment: If the B score of the test compound is less than the mean minus 3 times the standard deviation (SD) of the B scores of integrated ratios of all library compounds (B score Inhibitor Ratio <-3*SD), the ratio of initial fluorescence intensity is within 3 times the standard deviation plus the mean of the ratios of the complete library AND having a positive integrated ratio, the compound is designated in the Outcome as active (value=2) as an inhibitor of the TRPC4 channel. Otherwise, it is designated as inactive (value=1).
19. Score assignment: An active test compound is assigned a score between 5 and 100 by calculation of Integer ((Log10(abs(B score Inhibitor Ratio))-0.7)*250); they are normalized to the smallest and largest LOG10(B score Inhibitor Ratio), B score Inhibitor Ratio, as in the result definition. The inactive test compounds are assigned a score of 0.

List of reagents

1. TRPC4 and mu-Opioid Receptor-expressing HEK293 Cells (provided by Assay Provider Michael Zhu, Ohio State University)
2. PBS: pH7.4 (Invitrogen Cat#10010023)
3. Medium: Dulbecco's Modified Eagle Medium (D-MEM) (1X), liquid (high glucose) w/L-Glut (Sigma D5796-500ML)
4. Heat Inactivated Fetal Bovine Serum (Sigma, Cat# F2442)
5. L-Glutamine (Invitrogen, Cat#25030081)
6. 100x Penicillin-Streptomycin (Mediatech, Cat#30-001-CI)
7. CellStripper (Mediatech 25-056-Cl)
8. G418: (Invitrogen, Cat#11811-031)
9. Hygromycin#(Mediatech, Cat#30-240-CR)
10. HEPES (Sigma, Cat#H4034)
11. 10XHBSS (#Invitrogen Cat#14065056)
12. Pluronic F-127 (20% solution in DMSO) (Invitrogen Cat#P3000MP)
13. [D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin acetate salt (DAMGO) (Sigma Cat#E7384-10mg10MG)
14. Fluo-4 Calcium Assay Kit (Invitrogen, Cat # F14202)
15. Triple-layer flask (VWR, Cat #62407-082)
16. BD Biocoat 384-well plates (BD, Cat# (35)4663 and Lot #7346273)
Comment
Possible artifacts of this assay can include, but are not limited to: non-intended chemicals or dust, in or on wells of the microtiter plate, compounds that non-specifically modulate the cell host or the targeted activity, and compounds that quench or emit light or fluorescence within the well. All test compound concentrations reported are nominal; the specific concentration for a particular test compound may vary, based upon the actual sample provided by the MLSMR.
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1B score Inhibitor Ratio (10μM**)B score calculated based on the ratio of the test compound of the primary screen at a compound concentration of 10 uMFloat
2Initial Ratio (10μM**)Initial Ratio upon the addition of the compounds, as an indicator of compound fluorescence at a compound concentration of 10 uMFloat

** Test Concentration.
Additional Information
Grant Number: 1 R21 NS056942-01

Data Table (Concise)
Classification
PageFrom: